FrancophonIA/ELRC3.0 huggingface dataset:
English: Tell your doctor right away if you have: - signs of increased blood sugar levels such as excessive thirst, hunger or urination, weakness or onset of worsening of diabetes - worm-like movements of the tongue, or other uncontrolled movements of the tongue, mouth,
Danish: Fortæl det straks til lægen, hvis du har: - tegn på forhøjet blodsukker såsom overdreven tørst, sult eller vandladning, svaghed eller begyndende forværring af diabetes (sukkersyge) - vridende tungebevægelser eller andre ufrivillige bevægelser af tunge-, mund-, eller kæber, som kan sprede sig til arme og ben.
English: Asenapine is not indicated for the treatment of children and adolescent patients below 18 years (see section 4.2).
Danish: Asenapin er ikke indiceret til behandling af børn og unge under 18 år (se pkt.
English: Sycrest is not approved for the treatment of elderly patients with dementia and is not recommended for use in this particular group of patients.
Danish: Sycrest er ikke godkendt til behandling af ældre patienter med demens og anbefales ikke til denne gruppe af patienter.
English: Sycrest activity is primarily due to the parent compound.
Danish: Sycrests aktivitet skyldes hovedsagelig uomdannet asenapin.
English: There have been post-marketing reports of serious hypersensitivity reactions in patients treated with asenapine, including anaphylactic/anaphylactoid reactions, angioedema, swollen tongue and swollen throat (pharyngeal oedema).
Danish: Der har været post-marketing-indberetninger af alvorlige overfølsomhedsreaktioner hos patienter, der er blevet behandlet med asenapin, herunder anafylaktisk/anafylaktoid reaktion, angioødem, hævet tunge og svælg (faryngealt ødem).
English: All patients met the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria for bipolar I disorder, current episode manic (DSM-IV 296.4x), or mixed (DSM-IV 296.6x) and had a Young Mania Rating Scale (Y-MRS) score of ≥ 20 at screening and baseline.
Danish: Alle patienter opfyldte Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) diagnostiske kriterier for bipolar I lidelse, aktuel manisk episode (DSM-IV 296,4x) eller blandingsepisode (DSM-IV 296,6x) og havde en Young Mania Rating Scale (YMRS) score på ≥20 ved screening og baseline.
English: Asenapine may cause adverse effects such as somnolence, orthostatic hypotension, dizziness and extrapyramidal symptoms, which may lead to falls and, consequently, fractures or other injuries.
Danish: Asenapin kan give bivirkninger såsom somnolens, ortostatisk hypotension, svimmelhed og ekstrapyramidale symptomer, som kan medføre fald og dermed også frakturer eller andre skader.
English: - Do not push the tablet through the blister.
Danish: - Pres ikke resoribletten ud af blisterpakningen.
English: Falls may occur as a result of one or more adverse events such as the following: Somnolence, Orthostatic hypotension, Dizziness, Extrapyramidal symptoms.
Danish: Fald kan forekomme som et resultat af en eller flere bivirkninger såsom: somnolens, ortostatisk hypotension, svimmelhed, ekstrapyramidale symptomer.
English: If a patient develops signs and symptoms indicative of NMS Sycrest must be discontinued.
Danish: Sycrest skal seponeres, hvis en patient udvikler tegn og symptomer på NMS.
English: Sycrest should be used with caution in elderly patients and in patients with known cardiovascular disease (e.g., heart failure, myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration and hypovolemia).
Danish: Sycrest bør anvendes med forsigtighed hos ældre patienter og hos patienter med kendt kardiovaskulær sygdom (f.eks. hjertesvigt, myokardie infarkt eller iskæmisk hjertelidelse, ledningsforstyrrelser), cerebrovaskulær sygdom eller tilstande der prædisponerer for hypotension (f.eks. dehydrering og hypovolæmi).
English: If you miss one dose, take your next dose as usual.
Danish: Tag den næste dosis som du plejer, hvis du har glemt en dosis.
English: The clinically relevant adverse experiences identified in the paediatric bipolar and schizophrenia trials were similar to those observed in adult bipolar and schizophrenia trials.
Danish: De klinisk relevante bivirkninger, der blev identificeret i studier af bipolar lidelse og skizofreni hos den pædiatriske population, var de samme som blev set i studier af bipolar lidelse og skizofreni hos voksne.
English: Marketing Authorisation Holder N.V. Organon
Danish: Indehaver af markedsføringstilladelsen N.V.
English: 20 sublingual tablets 60 sublingual tablets 100 sublingual tablets
Danish: 20 resoribletter, sublinguale 60 resoribletter, sublinguale 100 resoribletter, sublinguale
English: In this short-term, fixed-dose controlled trial there was no evidence of added benefit with a 10 mg twice daily dose compared to 5 mg twice daily.
Danish: I dette kortvarige, kontrollerede studie med fast dosis var der ikke evidens for øget fordel af 10 mg to gange dagligt i forhold til 5 mg to gange dagligt.
English: In the same study, treatment with paroxetine 20 mg daily decreased the DX/DM ratio to 0.032.
Danish: I samme undersøgelse faldt DX/DM forholdet til 0,032 ved behandling med 20 mg paroxetin dagligt.
English: The most common adverse reactions (proportion of patients  5 % and at least twice placebo) reported in paediatric patients with schizophrenia were somnolence, sedation, akathisia, dizziness, and hypoaesthesia oral.
Danish: De hyppigst rapporterede bivirkninger (≥ 5% og mindst to gange frekvensen for placebo) hos pædiatriske patienter med skizofreni var døsighed, sedation, akatisi, svimmelhed og oral hypæstesi.
English: Do not use this medicine after the expiry date which is stated on the blister and on the carton.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned.
English: Direct glucuronidation (mediated by UGT1A4) and cytochrome P450 (primarily CYP1A2, with contributions of 2D6 and 3A4) mediated oxidation and demethylation are the primary metabolic pathways for asenapine.
Danish: Direkte glucoronidering (medieret af UGT1A4) og CYP-medieret (primært CYP1A2 med bidrag af 2D6 og 3A4) oxidation og demetylering er de primære metaboliske veje for asenapin.
English: Point estimates [95 % CI] for the change from baseline to endpoint in YMRS using LOCF analysis in the two studies were as follows: -11.5 [-13.0, -10.0] for asenapine vs -7.8 [-10.0, -5.6] for placebo and -10.8 [-12.3, -9.3] for asenapine vs -5.5 [-7.5, -3.5] for placebo.
Danish: Punkt estimaterne [95 % CI] for ændringerne fra baseline til endepunkt i YMRS ved brug af LOCF-analyse (last observation carried forward) i de to studier var følgende: -11,5 [-13,0, -10,0] for asenapin versus -7,8 [-10,0, -5,6] for placebo og -10,8 [-12,3, -9,3] for asenapin versus -5,5 [-7,5, -3,5] for placebo.
English: abnormal movements of the eyes, involuntary muscle contractions, slow movements, or restlessness - unpleasant sensations in the legs (also called restless legs syndrome) - speech problems - abnormal slow or fast heartbeat - middle heart block - abnormal electrocardiogram (prolongation of the QT interval) - low blood pressure upon standing - low blood pressure - tingling of the tongue or in the mouth - swollen or painful tongue - difficulty in swallowing - ulcers, soreness, redness, swelling, and blisters within the mouth - sexual dysfunction - lack of regular menstrual periods
Danish: (skælven), unormale bevægelser af øjet, ufrivillige muskelsammentrækninger, langsomme bevægelser eller rastløshed - ubehagelig fornemmelse eller uro i benene (også kaldet restless legs) - taleproblemer - unormalt langsom eller hurtig hjerterytme (puls) - hjerteblok - unormalt elektrokardiogram (forlængelse af QT-intervallet) - lavt blodtryk når man rejser sig - lavt blodtryk - prikkende fornemmelse i tungen eller i munden - hævelse eller smerte i tungen - synkebesvær - sår, ømhed, rødme, hævelse og blærer i munden - seksuel dysfunktion - manglende eller uregelmæssige menstruationsperioder.
English: For combination therapy a starting dose of 5 mg twice daily is recommended.
Danish: Ved kombinationsterapi anbefales en startdosis på 5 mg to gange dagligt.
English: The difference in LS mean change from baseline to Day 21 in the Y-MRS total score between asenapine 10 mg BID and placebo was -3.0 points (95 % CI [-5.6, -0.4]; p-value = 0.0244).
Danish: Forskellen i gennemsnitlig LS-ændring fra baseline til dag 21 i total YMRSscore mellem asenapin 10 mg to gange dagligt og placebo var -3,0 point (95 % CI [-5,6; -0,4]; p = 0,0244).
English: Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Danish: Sycrest er indiceret til behandling af moderate til svære maniske episoder ved bipolar affektiv sindslidelse (Bipolar I disorder) hos voksne.
English: Rare side effects (may affect up to 1 in 1,000 people) - changes in the levels of white blood cells - difficulties in focusing with the eyes - blood clots in blood vessels to the lungs causing chest pain and difficulty in breathing - muscle disease presenting as unexplained aches and pains - male breast enlargement - leakage of milk or fluid from the breast
Danish: Sjældne bivirkninger (kan påvirke op til 1 ud af 1.000) - ændringer i antallet af hvide blodlegemer - besvær med at fokusere med øjnene - blodpropper i blodkar til lungerne som forårsager brystsmerter og vejrtrækningsbesvær - muskellidelse som viser sig ved uforklarlige ømheder og smerter - forstørrelser af brysterne hos mænd - mælk eller væske siver ud fra brysterne.
English: The sublingual tablets are provided in peelable blisters containing 10 tablets each.
Danish: De sublinguale resoribletter leveres i oplukkelige (ved træk i den farvede flap) blisterpakninger, som indeholder 10 resoribletter hver.
English: Co-administration of asenapine with known inhibitors, inducers or substrates of these metabolic pathways has been studied in a number of drug-drug interaction studies (see section 4.5).
Danish: Samtidig administration af asenapin og kendte inhibitorer, inducere eller substrater af disse metaboliske veje, er blevet studeret i en række lægemiddel-interaktionsstudier (se pkt.
English: In a 3-week, placebo-controlled, randomized, fixed-dose efficacy and safety trial in paediatric patients 10 to 17 years of age with bipolar I disorder, the mean change from baseline to endpoint in weight for placebo and asenapine 2.5 mg, 5 mg, and 10 mg twice daily, was 0.48, 1.72, 1.62, and 1.44 kg, respectively.
Danish: I et 3-ugers placebokontrolleret, randomiseret studie vedrørende sikkerhed og virkning hos pædiatriske patienter i alderen 10-17 år med bipolar I lidelse var den gennemsnitlige vægtændring fra baseline til endepunkt for placebo og asenapin ved faste doser på 2,5 mg, 5 mg og 10 mg to gange dagligt henholdsvis 0,48, 1,72, 1,62 og 1,44 kg.
English: The clinically relevant adverse reactions identified in the paediatric trials were generally similar to those observed in the adult trials.
Danish: De klinisk relevante bivirkninger identificeret i de pædiatriske studier var generelt de samme, som blev set i voksenstudierne.
English: What Sycrest contains - The active substance is asenapine.
Danish: Sycrest indeholder: - Aktivt stof: Asenapin.
English: In a mass balance study, the majority of the radioactive dose was recovered in urine (about 50 %) and faeces (about 40 %), with only a small amount excreted in faeces (5-16 %) as unchanged compound.
Danish: I et massebalanceforsøg blev størstedelen af den radioaktive dosis genfundet i urin (ca. 50 %) og fæces (ca. 40 %).
English: The tablet should not be crushed.
Danish: Resoribletten må ikke knuses.
English: In rats, embryofoetal toxicity (increased post-implantation loss, decreased foetal weights, and delayed ossification) was observed following oral or intravenous administration during organogenesis or throughout gestation.
Danish: Hos rotter, blev der ved oral eller intravenøs indgift under organogenesen eller hele drægtighedsperioden observeret embryoføtal toksicitet (øget risiko for tab af graviditet, nedsat føtal vægt og forsinket ossifikation) observeret efter oral eller intravenøs indgift under organogenesen eller hele drægtighedsperioden.
English: In clinical trials, there were few adverse reactions related to abnormal prolactin levels reported.
Danish: I kliniske studier er der set få bivirkninger relateret til unormalt prolaktinniveau.
English: - Do not eat or drink for 10 minutes after taking the tablet.
Danish: - Du må ikke spise eller drikke i 10 minutter efter, at du har taget resoribletten.
English: Asenapine exhibits high affinity for serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5, 5-HT6, and 5-HT7 receptors, dopamine D2, D3, D4, and D1 receptors, α1 and α2-adrenergic receptors, and histamine H1 receptors, and moderate affinity for H2 receptors.
Danish: Asenapin udviser høj affinitet for 5-HT1A-, 5-HT1B-, 5-HT2A-, 5-HT2B-, 5-HT2C-, 5-HT5-, 5-HT6og 5-HT7-serotoninreceptorer; D2-, D3-, D4- og D1-dopaminreceptorer; α1- og α2-adrenerge receptorer samt H1-histaminreceptorer, og moderat affinitet for H2-receptorer.
English: If you stop taking Sycrest, you will lose the effects of this medicine.
Danish: Du mister virkningen af denne medicin, hvis du holder op med at tage Sycrest.
English: Maintenance of effect during the episode after 12 weeks of randomised treatment was demonstrated in this trial.
Danish: Der blev påvist vedligeholdelse af effekten op til 12 uger efter den primære randomisering.
English: From the clinical trials, it is concluded that clinically relevant body temperature dysregulation does not appear to be associated with asenapine.
Danish: Bedømt ud fra de kliniske studier er det blevet konkluderet, at asenapin ikke synes at være associeret med problemer med dysregulering af kropstemperaturen.
English: The tablet pack should not be cut or torn.
Danish: Blisterpakningen bør ikke rives i stykker eller flænses.
English: The recommended starting dose of Sycrest as monotherapy is 5 mg twice daily.
Danish: Den anbefalede initialdosis af Sycrest som monoterapi er 5 mg to gange dagligt.
English: In a second PK study using flavoured sublingual tablets, the 10 mg twice daily dose in a paediatric population (10 to 17 years of age, inclusive) resulted in an approximate dose-proportional increase in asenapine exposure compared to 5 mg twice daily.
Danish: I et andet farmakokinetisk studie med sublinguale resoribletter med smag medførte en dosis på 10 mg to gange dagligt i en pædiatrisk population (i alderen 10 til 17 år, begge inklusive) en omtrentlig dosisproportional stigning i asenapineksponeringen sammenlignet med 5 mg to gange dagligt.
English: The safety and efficacy of Sycrest was evaluated in 403 paediatric patients with bipolar I disorder who participated in a single, 3-week, placebo-controlled, double-blind trial, of whom 302 patients received Sycrest at fixed doses ranging from 2.5 mg to 10 mg twice daily.
Danish: Sycrests sikkerhed og virkning blev vurderet hos 403 pædiatriske patienter med bipolar I lidelse, som deltog i et enkelt, 3-ugers, placebokontrolleret, dobbeltblindet studie, hvoraf 302 patienter fik Sycrest i faste doser fra 2,5 mg til 10 mg to gange dagligt.
English: Electrocardiogram QT prolonged Sinus tachycardia
Danish: Sinusbradykardi Grenblok QT-forlængelse i ekg
English: Thus, Sycrest is not recommended in patients with severe hepatic impairment.
Danish: Sycrest anbefales derfor ikke til patienter med svært nedsat leverfunktion.
English: Hyperglycaemia or exacerbation of pre-existing diabetes has occasionally been reported during treatment with asenapine.
Danish: Der er set hyperglykæmi eller forværring af allerede eksisterende diabetes hos patienter i behandling med asenapin.
English: The most frequently reported adverse drug reactions (ADRs) associated with the use of asenapine in clinical trials were somnolence and anxiety.
Danish: De hyppigst rapporterede bivirkninger i kliniske studier med asenapin var døsighed og angst.
English: Therefore, Sycrest should be co-administered cautiously with medicinal products that are both substrates and inhibitors for CYP2D6.
Danish: Samtidig administration af Sycrest og lægemidler, der både er substrater og inhibitorer af CYP2D6 bør derfor håndteres med forsigtighed.
English: In a 12-week, placebo-controlled trial involving 326 patients with a manic or mixed episode of bipolar I disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of asenapine as adjunctive therapy resulted in superior efficacy to lithium or valproate monotherapy at week 3 (point estimates [95 % CI] for the change from baseline to endpoint in YMRS using LOCF analysis were -10.3 [-11.9, -8.8] for asenapine and -7.9 [-9.4, -6.4] for placebo) and at week 12 (-12.7 [-14.5, -10.9] for asenapine and -9.3 [-11.8, -7.6] for placebo) in the reduction of manic symptoms.
Danish: I et 12-ugers placebo-kontrolleret studie med 326 patienter, som havde manisk episode eller blandingstilstande af bipolar I lidelse, med eller uden psykotiske træk, som delvist ikke responderede på 2-ugers lithium eller valproat monoterapi ved terapeutiske serumniveauer, resulterede tilføjelse af asenapin som supplerende behandling i en bedre effekt af lithium eller valproat monoterapi i uge 3 (punktestimaterne [95 % CI] for ændringerne fra baseline til endepunkt i YMRS ved brug af LOCF analyse var -10,3 [-11,9, -8,8] for asenapin og -7,9 [-9,4, -6,4] for placebo) og i uge 12 (-12,7 [-14,5,10,9] for asenapin og -9,3 [-11,8, -7,6] for placebo) ved reduktion af maniske symptomer.
English: Based upon a LOCF analysis including all patients treated, the difference in least squares (LS) mean change from baseline to Day 21 in the Y-MRS total score between asenapine 5 mg BID and placebo was -3.1 points (95 % CI [-5.7, -0.5]; p-value = 0.0183).
Danish: På baggrund af en LOCF-analyse, som omfattede alle behandlede patienter, var forskellen i gennemsnitlig LS-ændring (mindste kvadraters metode) fra baseline til dag 21 i total YMRS-score mellem asenapin 5 mg to gange dagligt og placebo -3,1 points (95 % CI [5,7; -0,5]; p = 0,0183).
English: In vivo asenapine appears to be at most a weak inhibitor of CYP2D6.
Danish: In vivo synes asenapin højst at være en svag hæmmer af CYP2D6.
English: In subjects with severe hepatic impairment (Child-Pugh C), a 7-fold increase in asenapine exposure was observed (see section 4.2).
Danish: Hos patienter med svært nedsat leverfunktion (Child-Pugh C), blev en 7 gange forøgelse i asenapin eksponering observeret (se pkt.
English: No dose adjustment is required for patients with renal impairment.
Danish: Der kræves ingen dosisjusteringer for patienter med nedsat nyrefunktion.
English: The proportion of subjects with clinically significant weight gain (≥ 7 % weight gain from baseline at endpoint) in the short-term, flexible-dose bipolar mania trials was 6.5 % for asenapine compared to 0.6 % for placebo.
Danish: Andelen af patienter med klinisk signifikant vægtstigning (≥ 7 % vægtstigning fra baseline til endepunkt) i de kortvarige studier af bipolar mani med fleksibel dosering var 6,5 % for asenapin, sammenlignet med 0,6 % for placebo.
English: In a PK study using unflavoured sublingual tablets, at the 5 mg twice daily dose level, asenapine pharmacokinetics in adolescent patients (12 to 17 years of age, inclusive) are similar to those observed in adults.
Danish: I et farmakokinetisk studie med sublinguale resoribletter uden smag med doser på 5 mg to gange dagligt er farmakokinetikken for asenapin hos unge patienter (12 til 17 år, inklusive) den samme som hos voksne.
English: Common side effects (may affect up to 1 in 10 people) - weight gain - increased appetite - slow or sustained muscle contractions - restlessness - involuntary muscle contractions - slow movements, tremor - sedation - dizziness - nausea - change in taste - numb feeling of the tongue or in the mouth
Danish: Almindelige bivirkninger (kan påvirke op til 1 ud af 10) - vægtstigning - øget appetit - langsomme og vedvarende muskelsammentrækninger - rastløshed - ufrivillige muskelsammentrækninger - langsomme bevægelser, rysten - sløvhed - svimmelhed - kvalme
English: The incidence of dystonia in paediatric clinical trials using a gradual up-titration was similar to that seen in adult trials.
Danish: Incidensen af dystoni i kliniske studier med børn, hvor gradvis optitrering blev anvendt, var den samme som i studier med voksne.
English: - Each Sycrest 10 mg sublingual tablet contains 10 mg asenapine.
Danish: - Hver Sycrest 10 mg sublingual resoriblet indeholder 10 mg asenapin.
English: In one double-blind, fixed-dose, parallel-group, 3-week placebo controlled trial in subjects with bipolar I disorder experiencing an acute manic or mixed episode involving 367 patients of which 126 received placebo, 122 received asenapine 5 mg twice daily (BID), and 119 received asenapine 10 mg BID, the primary efficacy hypothesis was met.
Danish: I et dobbeltblindet, placebo-kontrolleret 3-ugers parallelgruppe-studie med fast dosis hos forsøgspersoner, der oplevede akut manisk eller blandingstilstand af bipolar I lidelse, og som involverede 367 patienter, hvoraf 126 fik placebo, 122 fik asenapin 5 mg to gange dagligt, og 119 fik asenapin 10 mg to gange dagligt, blev den primære hypotese vedrørende virkning bekræftet.
English: In clinical trials, cases of tardive dyskinesia were occasionally reported during treatment with asenapine.
Danish: I kliniske studier er tilfælde af tardiv dyskinesi sommetider set under behandling med asenapin.
English: Sycrest may cause sleepiness or sedation.
Danish: Sycrest kan medføre søvnighed eller virke sløvende.
English: Other serious ADRs are discussed in more detail in section 4.4.
Danish: 4.4 for nærmere oplysninger om andre alvorlige bivirkninger.
English: if you have ever been diagnosed with a condition whose symptoms include high body temperature and muscle stiffness (also known as neuroleptic malignant syndrome).
Danish: - hvis du er blevet diagnosticeret med en tilstand med symptomer i form af høj kropstemperatur og muskelstivhed (også kendt som Neuroleptisk Malignt Syndrom) - hvis du har oplevet unormale bevægelser af tungen eller ansigtet (tardiv dyskinesi).
English: There was a statistically significant higher incidence of patients with ≥ 7 % weight gain (from baseline to endpoint) compared to placebo (3.1 %) for Sycrest 2.5 mg twice daily (9.5 %) and Sycrest 5 mg twice daily (13.1 %).
Danish: Der var en statistisk signifikant højere incidens af patienter med ≥ 7% vægtstigning (fra baseline til endepunkt) sammenlignet med placebo (3,1%) for Sycrest 2,5 mg to gange dagligt (9,5%) og Sycrest 5 mg to gange dagligt (13,1%).
English: - Each Sycrest 5 mg sublingual tablet contains 5 mg asenapine.
Danish: - Hver Sycrest 5 mg sublingual resoriblet indeholder 5 mg asenapin.
English: Efficacy of Sycrest was not demonstrated in an 8-week, placebo-controlled, double-blind, randomized, fixed-dose trial in 306 adolescent patients aged 12-17 years with schizophrenia at doses of 2.5 and 5 mg twice daily.
Danish: Der blev ikke påvist virkning af Sycrest i et 8-ugers, placebokontrolleret, dobbeltblindet, randomiseret studie med faste doser hos 306 patienter i alderen 12-17 år med skizofreni, der fik doserne 2,5 og 5 mg to gange dagligt.
English: Sycrest is used to treat moderate to severe manic episodes associated with bipolar I disorder in adults.
Danish: Sycrest anvendes til behandling af moderate til svære maniske episoder ved bipolar affektiv sindslidelse (Bipolar I lidelse) hos voksne.
English: Cardiovascular monitoring is necessary to detect possible arrhythmias and management of overdose should concentrate on supportive therapy, maintaining an adequate airway oxygenation and ventilation, and management of symptoms.
Danish: Behandling af overdosering skal fokuseres på understøttende behandling omfattende opretholdelse af frie luftveje, ilttilskud og ventilation og symptombehandling.